Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(-/-) mice
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
OBJECTIVE: To investigate the role of urantide in the prevention and treatment of atherosclerosis (AS)-related liver and kidney injury by antagonizing the urotensin II/urotensin receptor (UII/UT) system and regulating the Wnt/β-catenin signaling pathway.
METHODS: Atherosclerotic ApoE-/- mice were treated with 20 mg/kg, 30 mg/kg, and 40 mg/kg urantide for 14 days.
RESULTS: When ApoE-/- mice developed AS, significant pathological changes occurred in the liver and kidney, and the UII/UT system in tissue was highly activated; furthermore, the Wnt/β-catenin signalling pathway was activated, and proteins related to this signalling pathway, such as GSK-3β, AXIN2, CK‑1, and APC, were significantly downregulated. After urantide treatment, the pathological damage to the liver and kidney was effectively improved, the activity of the UII/UT system was effectively inhibited, and the expression of the Wnt/β-catenin signalling pathway and related proteins was restored. Wnt/β-catenin signals were mainly localized in the cytoplasm, renal tubules, and interstitium.
CONCLUSION: Urantide could improve AS-related liver and kidney injury by antagonizing the UII/UT system, and the improvements in liver and kidney function in atherosclerotic ApoE-/- mice may be related to inhibition of the Wnt/β-catenin signalling pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Herz - (2023) vom: 20. Nov. |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Urantid lindert arteriosklerosebedingte Leber- und Nierenschädigungen über den Wnt/β-Catenin-Signalweg bei ApoE(−/−)-Mäusen |
|---|
| Beteiligte Personen: |
Xu, Yu-Hang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Revised 20.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00059-023-05219-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36476905X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36476905X | ||
| 003 | DE-627 | ||
| 005 | 20231226100126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00059-023-05219-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM36476905X | ||
| 035 | |a (NLM)37985514 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Yu-Hang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(-/-) mice |
| 246 | 3 | 3 | |a Urantid lindert arteriosklerosebedingte Leber- und Nierenschädigungen über den Wnt/β-Catenin-Signalweg bei ApoE(−/−)-Mäusen |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a OBJECTIVE: To investigate the role of urantide in the prevention and treatment of atherosclerosis (AS)-related liver and kidney injury by antagonizing the urotensin II/urotensin receptor (UII/UT) system and regulating the Wnt/β-catenin signaling pathway | ||
| 520 | |a METHODS: Atherosclerotic ApoE-/- mice were treated with 20 mg/kg, 30 mg/kg, and 40 mg/kg urantide for 14 days | ||
| 520 | |a RESULTS: When ApoE-/- mice developed AS, significant pathological changes occurred in the liver and kidney, and the UII/UT system in tissue was highly activated; furthermore, the Wnt/β-catenin signalling pathway was activated, and proteins related to this signalling pathway, such as GSK-3β, AXIN2, CK‑1, and APC, were significantly downregulated. After urantide treatment, the pathological damage to the liver and kidney was effectively improved, the activity of the UII/UT system was effectively inhibited, and the expression of the Wnt/β-catenin signalling pathway and related proteins was restored. Wnt/β-catenin signals were mainly localized in the cytoplasm, renal tubules, and interstitium | ||
| 520 | |a CONCLUSION: Urantide could improve AS-related liver and kidney injury by antagonizing the UII/UT system, and the improvements in liver and kidney function in atherosclerotic ApoE-/- mice may be related to inhibition of the Wnt/β-catenin signalling pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a G‑protein-coupled receptor 14 | |
| 650 | 4 | |a Kidney injury | |
| 650 | 4 | |a Liver injury | |
| 650 | 4 | |a Urantide | |
| 650 | 4 | |a Urotensin II | |
| 650 | 4 | |a Wnt/β-catenin pathway | |
| 700 | 1 | |a Xie, Jia-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tu |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Hai-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Herz |d 1993 |g (2023) vom: 20. Nov. |w (DE-627)NLM000324086 |x 1615-6692 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:20 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00059-023-05219-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 20 |c 11 | ||